Oscar Health and Policy: Why This Is No Shock
Oscar Health is a company deeply misunderstood by the market. That is not unusual. It often happens when a business operates at the intersection of technology, regulation, and a broken system. It becomes even more misunderstood when it does not play the traditional game of guiding short-term expectations. Oscar Health never promised it would be easy. But it is building the infrastructure that will define the next chapter of American healthcare. And that work is hard. It takes discipline. It takes vision. And it takes a management team with the scars to understand that political winds shift.
Over the last few weeks, headlines about the likely expiration of enhanced ACA subsidies have triggered a wave of fear. The stock fell. Analysts used the opportunity to question Oscar’s viability. Retail investors and institutions alike panicked, wondering if this would derail the company’s three-year profitability roadmap. But make no mistake. This was never a surprise to Oscar Health. It was never off the table. In fact, the entire business plan presented in 2024 already factored in the possibility of enhanced subsidies ending in 2025. Oscar knew this could happen. And they built accordingly.
This report breaks down the policy developments, the market overreaction, and why Oscar remains structurally prepared for a range of outcomes. It also examines the deeper issue behind the noise. Because this is not just about subsidies. This is about the future of American healthcare. And Oscar is building for that.
The Political Theater
Let us first clarify what actually happened. During the Trump administration’s second campaign push, several policy objectives were reiterated. Among them was the rollback of Biden-era healthcare expansions. These include the enhanced ACA subsidies that were part of emergency pandemic-era measures. The enhanced subsidies are set to expire at the end of 2025. Unless extended, this would result in a reversion to the original ACA subsidy structure. The enhanced subsidies significantly expanded affordability for lower- and middle-income individuals on the marketplace. The political debate now centers on whether those subsidies will be renewed, adjusted, or allowed to lapse.
This is not new information. Oscar Health and its executive team have stated clearly that they did not base their business plan on an assumption that the enhanced subsidies would continue. They presented long-term projections that accounted for the base ACA structure without enhancement. This is a critical distinction. Oscar is not a company begging for government help. It is a company navigating the system that exists while building technology that can help make it better.
The recent drop in the stock price reflects a market that does not read closely. Oscar’s investor day in 2024 laid out a roadmap for margin expansion, operational efficiency, and earnings per share growth that already assumed a world without enhanced subsidies. In fact, by 2027, they project over two dollars per share in earnings under those conditions. The market reacted to old news. Oscar already planned for this.
Building With Constraints
Oscar was founded on the idea that the healthcare system in the United States is broken. Not just a little inefficient, but fundamentally misaligned with the needs of the population. Insurance companies optimize for complexity. They profit from opacity. The system rewards volume, not outcomes. Oscar took a different approach from day one. It started with the individual market, where choice is personal, where experience matters, and where the user interface is not just a nice-to-have, but a competitive edge.
Over the years, Oscar has built a vertically integrated stack that allows it to manage members, providers, claims, and data in real time. Its platform is not a website with a nice design. It is a health system infrastructure engine that routes data, triages documents, and automates core processes in the background. That stack is not dependent on subsidies. It is built to reduce cost, increase accuracy, and improve outcomes across different reimbursement environments.
Oscar’s product is competitive with or without enhanced subsidies because it drives better engagement, more preventative care, and fewer gaps in service. That means better MLR performance, better risk adjustment scores, and ultimately better underwriting margins. The product does not vanish if subsidies decline. If anything, it becomes more valuable in a world where affordability becomes even more critical.
Oscar’s cost structure is increasingly scalable. Administrative expense per member has declined while service quality has improved. They are centralizing operational functions, rationalizing vendor spending, and automating claim workflows. This is what a technology company does. It finds leverage. It does not need to rely on lobbying or policy favors. It builds a product that works in the real world.
The Individual Market Is Not Going Away
There is a narrative among some investors that if subsidies end, the individual market will collapse. That is not accurate. The ACA marketplace is a permanent fixture. It is deeply embedded in the healthcare landscape. Millions of Americans rely on it. It has survived one administration change already. And while enhanced subsidies were additive, they are not the foundation. The base ACA law remains intact. That means the risk pool continues, the tax credits continue, and the need for competition continues.
Oscar is one of the few companies truly committed to the individual market. Others participate opportunistically. Oscar specializes. That focus gives it structural insight and data feedback loops that competitors lack. As others pull back, Oscar can gain share. And they have. Their recent open enrollment periods have shown strong retention and member satisfaction. The digital experience is sticky. People stay.
The growth of ICHRA, the individual coverage health reimbursement arrangement, adds another tailwind. More employers are offering defined contribution health benefits that allow workers to buy their own insurance on the individual market. That means more lives are entering Oscar’s addressable market. This is a secular shift that plays directly into Oscar’s strength. Employers get cost control. Workers get choice. Oscar gets members.
Management That Knows What It Is Doing
Mark Bertolini is not new to this game. He ran Aetna. He took it through crisis periods. He understands the regulatory cycles, the lobbying pressures, and the actuarial math. This is not an executive team hoping for the best. This is a team that has been through the worst and built through it. The rest of the leadership team has similar pedigree. They understand policy. They understand systems. And they understand that you do not build a lasting healthcare company by banking on temporary political gifts.
When Oscar laid out its three-year roadmap, it did so with discipline. It did not project blue-sky scenarios. It gave targets based on conservative assumptions. Operating profit. Net income. Cash flow. These are not dreams. They are goals grounded in execution. That execution has already begun. Medical loss ratios are improving. Overhead is declining. The path to profitability is visible.
The company is also attracting better risk. As underwriting improves, Oscar can price more competitively and still hit margin targets. Retention is strong. Member satisfaction is high. These are not vanity metrics. They are the foundation of a durable book of business.
The Broader Healthcare Crisis
Health insurance in the United States is no longer just an economic issue. It is a moral and societal one. Life expectancy is falling. Chronic diseases are rising. Obesity, diabetes, and mental health issues are affecting larger portions of the population than ever before. And yet the cost of care continues to rise. Fewer Americans can afford coverage. And even those who can often do not understand how to use it.
Oscar is trying to solve that. Not through slogans, but through systems. Its platform is built to engage. It sends nudges. It tracks preventative care. It flags gaps. It routes records. It verifies eligibility. It closes the loop. That is what infrastructure looks like. Not a portal. Not a call center. A real-time engine for managing health at scale.
This is what the country needs. A healthcare company that can operate within the system as it is, while helping shape it into something better. Oscar is not lobbying for favors. It is building a product that works. And it is doing so with a team that knows where the pitfalls are and how to navigate them.
Conclusion
The market reacted emotionally to headlines that Oscar’s management team has been modeling for years. This is not a surprise. It is a scenario. One that was expected. One that was planned for. The path to profitability is not dependent on political charity. It is based on operational discipline and technological scale. Oscar has both.
The individual market is not dead. It is evolving. And Oscar is ahead of that curve. With the rise of ICHRA, the deepening healthcare crisis, and the continued digitization of insurance, Oscar’s platform becomes more relevant every day. Their model is not thin. It is dense, connected, and becoming more profitable.
The management team is experienced. The systems are working. The vision is clear. Oscar does not need sympathy. It needs time to execute. And if it does, the upside remains substantial.
This is not a high-flying hype stock. It is a serious company building serious infrastructure in a sector that desperately needs it. Healthcare is not going away. And Oscar Health is one of the few companies treating it with the seriousness it deserves.
If you value this kind of deep, conviction-driven research, I invite you to become a Full Member of the FJ Research community. Join a group of long-term thinkers who are here to make bold bets on the future and hold them like owners.